ETON
Eton Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Eton Pharmaceuticals has 8 disclosed suppliers and 5 disclosed customers in SEC filings.
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+44.26%
vs ±10.6% implied · ×4.19
SentenceFor the years ended December 31, 2025, 2024 and 2023 , AnovoRx product sales represented 84.6 %, 93.6 % and 78.2 % of net revenues, respectively.
basisETON FY2025 revenue $80M
ETON 10-Kaccession 0001437749-26-009059
SentenceIn November 2024, the Company entered into a licensing agreement with AMMTeK. pursuant to which the Company has agreed to acquire the U.S. rights to Amglidia (glyburide oral suspension).
ETON 10-Kaccession 0001437749-26-009059
SentenceIn June 2021, the Company acquired U.S. and Canadian rights to Crossject's ZENEO® hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.
ETON 10-Kaccession 0001437749-26-009059
SentenceIn March 2020, the Company entered into an Exclusive License and Supply Agreement (the "Alkindi License Agreement") with Diurnal for marketing ALKINDI SPRINKLE® in the United States.
ETON 10-Kaccession 0001437749-26-009059
SentenceOn October 2, 2024, the Company and Ipsen Biopharmaceuticals, Inc. ("Ipsen"), a subsidiary of Ipsen S.A., entered into an Asset Purchase Agreement (the "Purchase Agreement"), whereby the Company agreed to acquire Increlex® (mecasermin injection) from Ipsen.
ETON 10-Kaccession 0001437749-26-009059
SentenceIn February 2026, the Company entered into a license agreement with Pierre Fabre Medicament Sas ("Pierre Fabre") for the exclusive rights to Hemangeol®, a product used for the treatment of proliferating infantile hermangioma.
ETON 10-Kaccession 0001437749-26-009059
SentenceIn March 2024, the Company acquired the U.S. rights to PKU GOLIKE® from Relief Therapeutics Holding SA.
ETON 10-Kaccession 0001437749-26-009059
SentenceIn March 2023, the Company acquired rare disease endocrinology product candidate ET- 600 from Tulex.
ETON 10-Kaccession 0001437749-26-009059
SentenceNet revenue of $31.6 million in 2023 included $5.5 million of licensing revenue from the sale of our neurology product royalty streams to Azurity in June 2023.
ETON 10-Kaccession 0001437749-26-009059
SentenceIn March 2025, the Company out-licensed the commercial rights to INCRELEX® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. ("Esteve").
ETON 10-Kaccession 0001437749-26-009059
SentenceThe Company's revenues and its accounts receivable balances are highly concentrated and consist of sales to and amounts due from AnovoRx and Optime Care for the Company's INCRELEX®, ALKINDI SPRINKLE®, KHINDIVI TM , GALZIN®, Carglumic Acid, Betaine Anhydrous and Nitisinone products, as well as from Pentec Health for sales of the Company's PKU GOLIKE® product.
ETON 10-Kaccession 0001437749-26-009059
SentenceThe Company's revenues and its accounts receivable balances are highly concentrated and consist of sales to and amounts due from AnovoRx and Optime Care for the Company's INCRELEX®, ALKINDI SPRINKLE®, KHINDIVI TM , GALZIN®, Carglumic Acid, Betaine Anhydrous and Nitisinone products, as well as from Pentec Health for sales of the Company's PKU GOLIKE® product.
ETON 10-Kaccession 0001437749-26-009059
shaded = implied · ▲▼ = realized
Eton Pharmaceuticals, Inc.
52.20
Expected move
Inputs8Q avg ±12.1%·×0.77·cheap
straddle ±14.7%
spot 52.18exp Nov 20ATM strike 50ATM straddle 9.02IV 88%